Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: Ceritinib is a novel triple negative breast cancer therapeutic agent

Fig. 5

Ceritinib inhibits FAK-YB-1 signaling pathways. (A) The total protein level of FAK and YB-1 were determined by WB assay in human breast cancer cell lines and (B) in human breast cancer tissues, Vinculin was used as a protein loading control. (C) Ceritinib treatment inhibited FAK activity in MDA-MB 231 and (D) SUM159PE cells. Cells were grown in DMEM with 10% FBS overnight. The cells were then treated with DMSO, 5 μM and 10 μM ceritinib for 4 h. The poteins including YB-1, FAK, AKT and phosphorlated YB-1, FAK, AKT were detected by western blot assay. (E) MDA-MB 231 cells grown in DMEM containing 40 ng/ml EGF and 10% FBS. The cells were treated with DMSO, 5 μM and 10 μM ceritinib for 4 h. The total and phosphorlated YB-1, FAK, AKT proteins were detected by western blot assay. (F) The Proposed mechanism. FAK inhibition by ceritinib may overcome YB-1 mediated chmoresistance

Back to article page